Centogene
201 articles about Centogene
-
CENTOGENE Receives Nasdaq Non-Compliance Notice
12/16/2022
Centogene N.V. has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5450 since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days.
-
CENTOGENE to Participate in Upcoming Conferences in December 2022
12/1/2022
Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its conference schedule for December 2022.
-
CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan
11/21/2022
Centogene N.V. today announced the appointment of Mary Sheahan as a member of the Supervisory Board, to be confirmed at the Company’s next General Meeting of Shareholders.
-
CENTOGENE to Participate in Upcoming Conferences in November 2022
11/10/2022
Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its conference schedule for November 2022.
-
CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network
11/3/2022
Centogene N.V. announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.
-
CENTOGENE to Participate in Upcoming Partnering Conferences in October 2022
10/6/2022
Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, announced its partnering conference schedule for October 2022.
-
CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics
10/3/2022
Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, announced reaching a significant milestone with the recruitment and genetic testing of 12,500 participants in the Rostock International Parkinson's Disease Study.
-
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September 2022
9/1/2022
Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, announced its investment and partnering conference schedule for September 2022.
-
CENTOGENE Reports First Quarter 2022 Financial Results
7/15/2022
Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2022, reaffirmed guidance, and provided a business update.
-
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
6/27/2022
Centogene N.V., the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, announced the voting results of the Company’s Annual General Meeting.
-
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
6/27/2022
Centogene N.V., the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, announced the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer of the Company, effective June 22, 2022.
-
Clover dosed the first participants in a Phase III study of its COVID-19 booster shot, while Global Access Diagnostics, Orbit Discovery, Proximie and more provide business and pipeline updates.
-
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
6/13/2022
Centogene N.V. announced that it has expanded its long-standing PYRUKYND® partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory FrameworkCE
5/25/2022
CENTOGENE today announced that its cloud-based Software as a Service (SaaS) platform for the identification, prioritization, and classification of human genetic variants is now CE-marked under the In Vitro Diagnostics Directive (98/79/EC).
-
CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics
5/23/2022
Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, as part of a consortium of organizations in genetics, announced the release of updated recommendations for Whole Genome Sequencing in the rare disease diagnostic setting.
-
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
5/19/2022
Centogene N.V. announced that Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites investors to participate via virtual one-on-one meetings.
-
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
4/28/2022
Centogene N.V. announced it has extended its partnership with Takeda to diagnose patients with rare metabolic and rare neurodegenerative diseases.
-
CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results
3/30/2022
Centogene N.V. today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, and provided a business update.
-
CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference
3/24/2022
Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that CEO Kim Stratton will speak at the sixteenth annual BIO-Europe Spring conference on March 31, 2022, at 3:00 p.m. CEST/9:00 a.m. EDT.